Lantern Pharma (LTRN) Stock Price, News & Analysis

Company Overview

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $3.10 to $3.41
• 50-Day Range: $2.94 to $4.15
• 52-Week Range: $2.79 to $11.99
• Volume: 38,603 shs
• Average Volume: 126,974 shs
• Market Capitalization: $33.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

LTRN Stock Analysis - Frequently Asked Questions

How have LTRN shares performed this year?

Lantern Pharma's stock was trading at $4.28 at the beginning of the year. Since then, LTRN stock has decreased by 26.6% and is now trading at $3.14.
View the best growth stocks for 2024 here.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.09.

When did Lantern Pharma IPO?

Lantern Pharma (LTRN) raised $26 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Who are Lantern Pharma's major shareholders?

Top institutional shareholders of Lantern Pharma include Westside Investment Management Inc. (0.28%). Insiders that own company stock include Leslie W Kreis and Aaron GL Fletcher.
View institutional ownership trends.

How do I buy shares of Lantern Pharma?

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LTRN
• CUSIP: N/A
• CIK: 1763950
• Web: www.lanternpharma.com
• Phone: 972-277-1136
• Fax: N/A
• Employees: 20
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($1.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,960,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.91%
• Return on Assets: -51.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.31
• Quick Ratio: 8.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.76 per share
• Price / Book: 0.84

Miscellaneous

• Outstanding Shares: 10,785,000
• Free Float: 9,997,000
• Market Cap: $33.86 million
• Optionable: Optionable
• Beta: 1.56